News | September 23, 2010

First Human Ultrasound Procedure Successfully Reduces MR

September 23, 2010 - The first-in-human procedure to use ultrasound therapy to treat mitral regurgitation (MR) has been successfully completed. The data from the study, which used ReCor Medical’s ultrasound therapy, will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 meeting in Washington, D.C.

The procedure was performed by Karl-Heinz Kuck, M.D., Hamburg, Germany on a 79-year-old male with severe MR (3+). The procedure took less than 90 minutes reduced MR to 1+.

“The device was extremely easy to use and the fact that you do not implant anything makes this a breakthrough in mitral valve repair,” Kuck said.

“Our ultrasound therapy is a whole new modality for treating MR,” said Mano Iyer, founder and CEO of ReCor Medical. “Ultrasound creates heat. Heat shrinks collagen. Shrinkage reduces the mitral valve annulus, and annular reduction reduces MR.”

“As a cardiac surgeon, I believe this is an historic moment, as this represents the first time ever that a patient has been treated without leaving anything behind,” said professor Jacques Séguin, M.D., Ph.D., founder and former chairman/CEO of CoreValve and chairman of ReCor. “We also see an application for tricuspid regurgitation, which means we can truly revolutionize the treatment of cardiac valve insufficiency.”

For more information:

Related Content

PinnacleHealth First in Pennsylvania to Implant Sentinel Cerebral Protection System
News | Embolic Protection Devices| August 23, 2017
PinnacleHealth is the first hospital in Pennsylvania and one of the first 10 in the country to introduce new technology...
CMS Awards New Technology Add-on Payment for Perceval Sutureless Aortic Heart Valve
News | Heart Valve Technology| August 22, 2017
August 22, 2017 — LivaNova PLC announced its Perceval ...
Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Overlay Init